CSPG4 and triple-negative breast carcinoma: Furthermore, a more recent preclinical study evaluating mAb 225.28 radiolabeled with 212Pb showed efficacy against triple negative breast cancer cells expressing CSPG4, both in vivo and in vitro (109).